Plasma androgen receptor (pAR) status and activity of taxanes in metastatic castration resistant prostate cancer (mCRPC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.5074
Abstract: 5074Background: Plasma AR (pAR) gain identifies CRPC with worse outcome on abiraterone (abi) or enzalutamide (enza). We aimed to evaluate whether taxanes in CRPC are active regardless of AR status ... read more here.
Keywords: status; plasma; par; plasma androgen ... See more keywords